[go: up one dir, main page]

SE0004671D0 - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation

Info

Publication number
SE0004671D0
SE0004671D0 SE0004671A SE0004671A SE0004671D0 SE 0004671 D0 SE0004671 D0 SE 0004671D0 SE 0004671 A SE0004671 A SE 0004671A SE 0004671 A SE0004671 A SE 0004671A SE 0004671 D0 SE0004671 D0 SE 0004671D0
Authority
SE
Sweden
Prior art keywords
formulation
pharmaceutical formulation
erasable
drug
dissolved
Prior art date
Application number
SE0004671A
Other languages
English (en)
Inventor
Inger Norden
Peter Fyhr
Catarina Carling
Original Assignee
Amarin Dev Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Dev Ab filed Critical Amarin Dev Ab
Priority to SE0004671A priority Critical patent/SE0004671D0/sv
Publication of SE0004671D0 publication Critical patent/SE0004671D0/sv
Priority to US09/788,414 priority patent/US20020114831A1/en
Priority to US10/342,222 priority patent/US7338667B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0004671A 2000-12-15 2000-12-15 Pharmaceutical formulation SE0004671D0 (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0004671A SE0004671D0 (sv) 2000-12-15 2000-12-15 Pharmaceutical formulation
US09/788,414 US20020114831A1 (en) 2000-12-15 2001-02-21 Pharmaceutical formulation
US10/342,222 US7338667B2 (en) 2000-12-15 2003-01-15 Pharmaceutical formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0004671A SE0004671D0 (sv) 2000-12-15 2000-12-15 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE0004671D0 true SE0004671D0 (sv) 2000-12-15

Family

ID=20282266

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0004671A SE0004671D0 (sv) 2000-12-15 2000-12-15 Pharmaceutical formulation

Country Status (2)

Country Link
US (2) US20020114831A1 (sv)
SE (1) SE0004671D0 (sv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
PA8578501A1 (es) * 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
SG164375A1 (en) * 2004-08-13 2010-09-29 Boehringer Ingelheim Int Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
DE602005024570D1 (de) * 2004-08-13 2010-12-16 Boehringer Ingelheim Pharma Tablettenformulierung mit verlängerter freisetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon, herstellungsverfahren und verwendung dafür
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
EP1830886B1 (en) * 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
BRPI0608780A2 (pt) * 2005-04-28 2010-11-09 Eisai R&D Man Co Ltd composição contendo fármaco anti-demência
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
KR20090109130A (ko) * 2007-02-09 2009-10-19 포니아드 파마슈티칼즈, 인크. 캡슐화된 피코플라틴
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20080268067A1 (en) * 2007-03-09 2008-10-30 Llinas Rodolfo R Methods and Compositions for Treating Thalamocortical Dysrhythmia
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
EP2249827A4 (en) * 2008-02-08 2012-05-30 Poniard Pharmaceuticals Inc USE OF PICOPLATIN AND CETUXIMAB IN THE TREATMENT OF COLORECTAL CANCER
US8986739B2 (en) 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
CN113750069B (zh) * 2021-11-09 2022-03-01 北京联嘉医药科技开发有限公司 一种硝苯地平缓释片及其制备方法
CN114432254B (zh) * 2021-12-30 2023-05-16 南通联亚药业股份有限公司 一种硝苯地平控释片

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
EP0852141A1 (en) 1996-08-16 1998-07-08 J.B. Chemicals & Pharmaceuticals Ltd. Nifedipine containing pharmaceutical extended release composition and a process for the preparation thereof
ID23503A (id) 1997-07-01 2000-04-27 Pfizer Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina
US6555139B2 (en) * 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization

Also Published As

Publication number Publication date
US20020114831A1 (en) 2002-08-22
US7338667B2 (en) 2008-03-04
US20030108606A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
SE0004671D0 (sv) Pharmaceutical formulation
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
ATE238813T1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
ATE244556T1 (de) Biologisch abbaubare ph/thermosensitive hydrogele zur verzörgerten freisetzung biologisch aktiver stoffe
PA8458101A1 (es) Formas de dosificacion farmaceuticas solidas
CU23440B7 (es) Composición de liberación sostenida de pramipexol
AR042536A1 (es) Dispersiones solidas que comprenden un farmaco higroscopico y/o delicuescente
NO2013019I2 (no) Aliskiren eller et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.
AR048250A1 (es) Productos de pelicula que tienen propiedades de disgregacion controlada
CL2004000837A1 (es) Pelicula ingerible para adherirse y disolverlo en la cavidad oral, que comprende un polimero soluble en agua, un enmascarador de sucralosa y un agente farmaceuticamente activo.
AR003908A1 (es) Tableta de liberacion controlada
PA8548801A1 (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
ATE314054T1 (de) Osmotisches verabreichungssystem für lösliche dosen
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
ES2151464T1 (es) Preparacion para aplicacion externa que comprende tranilast y procedimiento para producirla.
ECSP044974A (es) Formulación de suspensión oral estabilizada
EE9900589A (et) Farmatseutilised kompositsioonid limaskestale kandmiseks
DK0950403T3 (da) Emulsioner til in-situ leveringssystemer
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
AR032642A1 (es) Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral.
DE60041691D1 (de) Ph-unabhängige pharmazeutische formulierungen mit verlängerter freisetzung
SE0001916D0 (sv) Novel formulation